ovarian cancer
Roche gains new licence for blockbuster oncology drug
August 6, 2014Research and Development, Sales and Marketing EC, Roche, avastin, ovarian cancer
Roche’s blockbuster cancer treatment Avastin now has a new European licence to treat women with a certain type of ovarian …
NICE recommends ovarian cancer drug Caelyx
September 27, 2013Sales and Marketing NICE, Yondelis, ovarian cancer
AstraZeneca begins olaparib programme
September 4, 2013Sales and Marketing AstraZeneca, olaparib, ovarian cancer
AstraZeneca has begun recruitment in its Phase III programme for olaparib, a potential first-in-class oral poly ADP ribose polymerase (PARP) …
New ovarian cancer screening shows promise
August 27, 2013Research and Development, Sales and Marketing ovarian cancer, screening
A new screening process for ovarian cancer is showing encouraging results, according to researchers in the US. In a trial …
Ovarian cancer charity wins GSK/King’s Fund award
May 21, 2012Medical Communications, Sales and Marketing GSK, awards, charity, king's fund, ovarian cancer
A charity which aims to increase the chances of survival for patients with a poorly-treated form of cancer is to …
AstraZeneca posts drug failures, takes $382m hit
December 20, 2011Research and Development, Sales and Marketing AstraZeneca, depression, ovarian cancer
AstraZeneca has taken a major blow to its late stage pipeline, with one of its key cancer drugs now being …
Roche’s Avastin set for new ovarian cancer indication in Europe
September 26, 2011Sales and Marketing avastin, ovarian cancer
Roche’s Avastin has gained the backing of European regulatory advisors for a new indication in ovarian cancer. The European Medicines …
NICE gives final no to PharmaMar’s Yondelis
April 27, 2011Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer
A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …
NICE rejects PharmaMar’s ovarian cancer drug Yondelis
March 14, 2011Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer
NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …
Roche eyes ovarian cancer expansion for Avastin
February 8, 2011Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer
Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …
Ovarian cancer trial boost for Avastin
July 5, 2010Research and Development Roche, avastin, ovarian cancer
Roche’s blockbuster oncology drug Avastin has met its primary endpoint of improving progression-free survival in women with ovarian cancer in …
NICE rejects Yondelis in ovarian cancer
June 21, 2010Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer
New cancer treatment Yondelis has been rejected by NICE in a preliminary ruling on its use in relapsed ovarian cancer. …
Latest content
